Skip to main content
Medical information Clinical review pending

Genetic Testing

NTHL1 Gene Familial Adenomatous Polyposis Type 3 Genetic Test

The NTHL1 Gene Familial Adenomatous Polyposis Type 3 Genetic Test uses Next Generation Sequencing (NGS) to identify mutations in the NTHL1 gene, which are associated with an increased risk of developing certain cancers, particularly colorectal cancer. Genetic counseling is recommended before testing.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results
3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
No specific fasting is required. Confirm with the laboratory before booking. A clinical history assessment and genetic counseling session are advised prior to testing.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the NTHL1 Gene Familial Adenomatous Polyposis Type 3 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Family history of adenomatous polyposis
  • ✓Family history of colorectal cancer, especially early-onset
  • ✓Presence of multiple colorectal polyps
  • ✓Personal history of Familial Adenomatous Polyposis (FAP)
  • ✓Unexplained gastrointestinal symptoms in individuals with relevant family history
  • ✓Individuals considering prophylactic surgery due to high risk
02

In plain language

What this test helps you understand

Identifies mutations in the NTHL1 gene associated with Familial Adenomatous Polyposis Type 3, indicating an increased risk for colorectal cancer and potentially other cancers. Helps guide surveillance and preventive strategies.
The NTHL1 Gene Familial Adenomatous Polyposis Type 3 NGS Genetic DNA Test is a diagnostic tool used to assess genetic risks associated with familial adenomatous polyposis (FAP), a condition linked to a higher likelihood of developing colorectal cancer. This test utilizes advanced Next Generation Sequencing (NGS) technology to analyze the NTHL1 gene, providing valuable information for early intervention and management of potential cancer risks.

This genetic test specifically looks for mutations in the NTHL1 gene, which are known to be associated with familial adenomatous polyposis type 3. By examining your genetic material, the test can help identify if you have an increased risk for developing certain types of cancers, especially colorectal cancer.

Individuals with a family history of adenomatous polyposis or colorectal cancer, particularly those diagnosed at a young age, may benefit from this test. Other reasons to consider testing include the presence of multiple polyps in the colon or unexplained gastrointestinal symptoms. A personal history of FAP or related syndromes is also an indication for testing.

Taking this test can offer several advantages, including early identification of a genetic predisposition to cancer, enabling informed decisions about surveillance and preventive measures. It can provide peace of mind and guide tailored management strategies developed with your healthcare provider.

Results will indicate whether mutations in the NTHL1 gene were detected. It is crucial to discuss these results with a qualified healthcare provider or genetic counselor to understand their implications and determine appropriate next steps, such as increased surveillance or preventive strategies.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific fasting is required. Confirm with the laboratory before booking. A clinical history assessment and genetic counseling session are advised prior to testing.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS) analysis of the NTHL1 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only analyzes the NTHL1 gene. It does not detect mutations in other genes associated with FAP or other cancer syndromes. A negative result does not completely rule out a genetic predisposition to cancer. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

FAP is an inherited condition characterized by the development of numerous polyps in the colon and rectum, significantly increasing the risk of colorectal cancer.
Individuals with a family history of FAP or colorectal cancer, especially if diagnosed at a young age, should consider this test.
The test involves analyzing a sample of your blood or DNA to look for specific mutations in the NTHL1 gene.
Results should be discussed with a healthcare provider or genetic counselor to understand their meaning and implications for your health.
Yes, genetic counseling before and after testing is strongly recommended to help understand the test, its implications, and the results.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp